

Harnessing the potential of fermentation for healthy and sustainable foods

Submission date 26/03/2024	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 27/03/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 26/01/2026	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Evidence suggests that the gut microbiota play an important role in host health and the development of non-communicable diseases. An increasing number of studies have shown that fermented products, particularly fermented dairy products, influence metabolic health. This study aims to demonstrate the health impacts of daily consumption of kefir on healthy and metabolic syndrome (MetS) subjects and to establish how fermented food consumption shapes the gut microbiome and provides health benefits to the consumer.

Who can participate?

Healthy volunteers aged between 18 and 60 and patients with MetS aged between 18 and 65 years old

What does the study involve?

This study is a randomised, double-blind, double arm with a parallel design trial involving three research centres: Imperial College London (IC) in the UK, Centre De Recherche en Nutrition Humaine Rhône-Alpes (CRNH-RA) in France, and the University of Naples Federico II (UNINA) in Italy. The UK site will recruit 21 healthy participants and 30 participants with MetS, while the Italian site will enrol 20 healthy participants and 30 participants with MetS. The French site will include 21 healthy participants. Participants will be randomised to consume 200 ml of intervention kefir daily, while participants from the placebo group will be asked to consume 200 ml of placebo daily. Each participant will attend the clinical research centre at their respective study site at baseline and once a month for 6 months.

What are the possible benefits and risks of participating?

The potential benefit of the study is that kefir is suggested to have a beneficial effect on gut health, although it cannot be guaranteed that this will be the case in this study, nor can participants expect direct benefits. Upon request, participants can receive results from blood, stool, and urine analysis to provide an overview of their metabolic health. Fasting blood samples and blood pressure taken throughout the visit can provide insight into aspects of chronic disease risk, such as Type 2 diabetes and cardiovascular disease.

If the study reveals any previously unknown health issues, such as abnormal kidney test results or possible type 2 diabetes, potential participants will be informed immediately, and urgent assessments will be arranged within the hospital if needed. Their GP will also be informed of their participation and any clinically significant blood test results. Procedures like recording weight and height pose no health risks. Self-collection of stool and urine samples may lead to contamination, but this risk has been minimised through the use of hygienic, easy-to-use collection kits. Blood sampling may cause mild discomfort, bruising, or localised infection, but these risks are reduced by having trained professionals perform the procedure under aseptic conditions.

Where is the study run from?

Imperial College London (IC) in the UK, Centre De Recherche en Nutrition Humaine Rhône-Alpes (CRNH-RA) in France, and the University of Naples Federico II (UNINA) in Italy

When is the study starting and how long is it expected to run for?

April 2024 to March 2029

Who is funding the study?

1. UK Research and Innovation (UKRI)
2. European Horizon

Who is the main contact?

Dr Isabel Garcia Perez, i.garcia-perez@imperial.ac.uk

Contact information

Type(s)

Scientific, Principal investigator

Contact name

Dr Isabel Garcia Perez

ORCID ID

<https://orcid.org/0000-0001-8398-0603>

Contact details

10th Floor Commonwealth Building, Hammersmith Campus, Imperial College London

London

United Kingdom

W12 0NN

+44 (0)7704344683

i.garcia-perez@imperial.ac.uk

Type(s)

Public

Contact name

Mrs Yiwei Vally Wu

ORCID ID

<https://orcid.org/0000-0001-9254-802X>

Contact details

10th Floor Commonwealth Building, Hammersmith Campus, Imperial College London
London
United Kingdom
W12 0NN
+44 (0)7717000746
y.wu18@imperial.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

337740

Central Portfolio Management System (CPMS)

61519

Study information

Scientific Title

Determination of the health impacts of milk kefir on healthy and metabolic syndrome subjects
DOMINO study

Acronym

DOMINO

Study objectives

Daily consumption of milk kefir for 6 months will positively impact glucose and lipid metabolism along with inflammatory status and gut microbiome in healthy and Metabolic Syndrome volunteers.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 16/01/2024, Comitato Etico Campania 3 (Via Antonio Cardarelli, 9, Napoli, 80131, Italy; +39 081 7473312; segreteria@comitatoeticocampania3.it), ref: Protocol n.05/2024
2. approved 05/03/2024, Comité de Protection des Personnes Nord Ouest II (Bâtiment de formation- RDC – Hôpital Nord - Place Victor Pauchet, Amiens, 80054, France; 03226685; cpp.nordouest2@chu-amiens.fr), ref: 2023-A02507-38
3. approved 03/05/2024, Yorkshire & The Humber - Bradford Leeds Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, United Kingdom; +44 (0)2071048083; bradfordleeds.rec@hra.nhs.uk), ref: 24/YH/0076

Study design

Multicentre interventional double-blind double-arm randomized controlled study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Assessing the effects of kefir consumption in both healthy subjects and those with metabolic syndrome (MetS).

Interventions

Current interventions as of 26/01/2026:

The study aims to investigate the effects of kefir consumption in both healthy subjects and those with metabolic syndrome. Participants will be randomised using randomisation software to a kefir group that is asked to consume 200 ml of kefir daily and a placebo group that is asked to consume 200 ml of placebo daily. Each participant will attend the clinical research centre at their respective study site at baseline and then monthly for the duration of the intervention (4 months for healthy participants and 3 months for participants with metabolic syndrome). The study sites include Imperial College London (IC) in the UK, Centre De Recherche en Nutrition Humaine Rhône-Alpes (CRNH-RA) in France, and the University of Naples Federico II (UNINA) in Italy. At each time point, anthropometric measurements will be taken, and urine, stool, and blood samples will be collected.

Previous interventions:

The study aims to investigate the effects of kefir consumption in both healthy subjects and those with metabolic syndrome. Participants will be randomised using randomisation software to a kefir group that is asked to consume 200 ml of kefir daily and a placebo group that is asked to consume 200 ml of placebo daily. Each participant will attend the clinical research centre at their respective study site at baseline and once a month for 6 months. The study sites include Imperial College London (IC) in the UK, Centre De Recherche en Nutrition Humaine Rhône-Alpes (CRNH-RA) in France, and the University of Naples Federico II (UNINA) in Italy. At each time point, anthropometric measurements will be taken, and urine, stool, and blood samples will be collected.

Intervention Type

Supplement

Primary outcome(s)

Current primary outcomes as of 26/01/2026:

The effects of daily kefir consumption on markers of glucose metabolism in healthy volunteers are measured using fasting blood glucose (FG), glycated haemoglobin (HbA1C), and homeostasis model assessment-insulin resistance (HOMA-IR); and, in subjects with metabolic syndrome (MetS) are measured using insulin and homeostasis model assessment-insulin resistance (HOMA-IR), as follows:

1. Fasting blood glucose (FG) is measured using the PAP peroxidase method at baseline and monthly.
2. Glycated haemoglobin (HbA1C) is measured using capillary electrophoresis at baseline and month 3.

3. Homeostasis model assessment-insulin resistance HOMA-IR, calculated using the formula $\text{HOMA-IR} = \text{Fasting insulin } (\mu\text{U/mL}) \times \text{fasting glucose (mg/dL)} / 405$, is measured using Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and monthly.

Previous primary outcomes:

The effects of daily kefir consumption on markers of glucose metabolism in healthy volunteers are measured using fasting blood glucose (FG), glycated haemoglobin (HbA1C), and homeostasis model assessment-insulin resistance (HOMA-IR); and, in subjects with metabolic syndrome (MetS) are measured using insulin and homeostasis model assessment-insulin resistance (HOMA-IR), as follows:

1. Fasting blood glucose (FG) is measured using the PAP peroxidase method at baseline and months 1, 2, 3, 4, 5, and 6
2. Glycated haemoglobin (HbA1C) is measured using capillary electrophoresis at baseline and months 3 and 6
3. Homeostasis model assessment-insulin resistance HOMA-IR, calculated using the formula $\text{HOMA-IR} = \text{Fasting insulin } (\mu\text{U/mL}) \times \text{fasting glucose (mg/dL)} / 405$, is measured using Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and months 1, 2, 3, 4, 5, 6

Key secondary outcome(s)

Current secondary outcomes as of 26/01/2026:

1. Measures of lipid metabolism (blood cholesterol, triglyceride, HDL cholesterol and LDL cholesterol) are measured by Nuclear Magnetic Resonance at baseline and month 4 in the healthy cohort, and at baseline and month 3 in participants with metabolic syndrome.
2. Inflammatory status (CRP, IL-6, IL-8, TNF-alpha and leptin) is measured using Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and month 4 in the healthy cohort, and at baseline and month 3 in participants with metabolic syndrome.
3. Gut permeability and changes to the gut microbiome (microbial diversity, microbial composition) measured by metagenomics at baseline and monthly.

Previous secondary outcomes:

1. Measures of lipid metabolism (blood cholesterol, triglyceride, HDL cholesterol and LDL cholesterol) are measured by Nuclear Magnetic Resonance at baseline and month 6
2. Inflammatory status (CRP, IL-6, IL-8, TNF-alpha and leptin) is measured using Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and month 6
3. Gut permeability and changes to the gut microbiome (microbial diversity, microbial composition) measured by metagenomics at baseline and months 1, 2, 3, 4, 5, and 6

Completion date

01/03/2029

Eligibility

Key inclusion criteria

Healthy participants inclusion criteria:

1. General good health
2. Both gender
3. BMI between 20 and 29.9 kg/m²
4. Aged between 18 and 60 years old

5. Willing to take one daily portion of kefir or placebo and to follow the procedures as well as a 2-3h metabolic exploration day every month of follow-up
6. Written informed consent

Metabolic syndrome participants inclusion criteria:

1. Aged between 18 and 65 years old
2. Subjects diagnosed with metabolic syndrome according to the International Diabetes Federation (IDF) criteria
3. Low consumption (max intake 3 servings/week) of kefir or supplements/foods labelled as having probiotic effect during the prior 3 months
4. Consumption of fruits and vegetables \leq 3 servings per day
5. Willing to take one daily portion of kefir or placebo and to follow the procedures as well as a 2-3h metabolic exploration day every month of follow-up
6. Written informed consent

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Total final enrolment

129

Key exclusion criteria

Healthy participants exclusion criteria:

1. BMI \geq 30 kg/m²
2. Gastrointestinal disorders of any kind
3. Previous abdominal surgery
4. Lactose intolerance or intolerance to the study products
5. Blood triglyceride > 150 mg/dL
6. Blood total cholesterol > 240 mg/dL or HDL-cholesterol <40 mg/dl (men) or < 50 mg/dl (women)
7. Blood pressure \geq 140/90 mm Hg or taking blood pressure medications
8. Fasting blood glucose >105 mg/dL
9. Pharmacological treatments of any type at enrolment and in the 2 months before the study
10. Consumption of supplements or foods labelled as having a probiotic effect prior 3 months
11. Consumption of Kefir > 3 servings/week during the prior 3 months
12. Menopause women

13. Alcohol consumption exceeding 30g of alcohol/day (1 alcoholic beverage dose = 10g of alcohol) or proven abuse or dependence on another drug. Consumption of more than 3 alcoholic beverages per day is considered abusive. An alcoholic beverage corresponds, for example, to 30 ml of spirits, 120 ml of wine or 330 ml of beer
14. Consumption of fruits and vegetables > 5 servings per day
15. Dietary fibre intake > 30g/1000 kcal per day
16. Pregnant, parturient or breast-feeding woman; for women of childbearing age: positive urine pregnancy test
17. Antibiotics consumption over the prior 1 month before the trial
18. Daily use of laxatives in the 3 months before explorations, or use of drugs that may strongly interfere with the composition of the intestinal microbiota
19. Contemporary participation in other studies
20. Blood donors in the last 2 months
21. Use of lipid-lowering drugs
22. Under antidiabetic treatment
23. Individuals who have lost/ gained ≥ 3 kg in the last 3 months
24. Individuals with unstable medical or psychological conditions which, in the investigator's opinion, could lead the volunteer to be non-compliant or uncooperative during the study, or which could compromise the volunteer's safety or participation in the study
25. Pre-diabetes, type 1 or 2 diabetes
26. Cancer
27. Infectious diseases
28. Cardiovascular disease
29. Hypertension
30. Severe eating disorders (anorexia/bulimia, binge eating disorder, noctophagia, etc.)
31. Severe chronic renal failure (GFR<60mL/min)
32. Hepatocellular insufficiency
33. Exocrine pancreatic insufficiency
34. Known endocrine pathology inducing hyperglycaemia (uncontrolled dysthyroid, acromegaly, hypercorticism, etc.)
35. Previous intestinal or abdominal surgery, bariatric surgery, gallbladder surgery, polyp removal, known gastroparesis, total gastrectomy or colectomy
36. Pathology detectable on clinical examination and medical questioning that may interfere with the study's evaluation criteria
37. Adult subject to a legal protection measure (guardianship, curatorship)
38. Person deprived of liberty by judicial or administrative decision

Metabolic syndrome participants exclusion criteria:

1. Lactose intolerance
2. Type 1 diabetes
3. Abnormal thyroid hormone levels
4. Chronic gastrointestinal system disease
5. Cancer
6. Severe liver disease
7. Kidney insufficiency
8. Immunodeficiency
9. Taking medication to regulate blood glucose (except metformin) or lipid levels (added 26/01 /2026) for less than 3 months
10. Taking antibiotics prior to one month of the study
11. Taking supplement which may affect the metabolic outcomes such as prebiotic or omega-3
12. Dieting for weight loss or for another disease
13. Pregnant, parturient, or breast-feeding woman; for women of childbearing age: positive

urine pregnancy test

14. Alcohol consumption exceeding 30g of alcohol/day (1 alcoholic beverage dose = 10g of alcohol) or proven abuse or dependence on another drug. Consumption of more than 3 alcoholic beverages per day is considered abusive. An alcoholic beverage corresponds, for example, to 30 ml of spirits, 120 ml of wine or 330 ml of beer

15. Contemporary participation in other studies

16. Blood donors in the last 2 months

17. Pathology detectable on clinical examination and medical questioning that may interfere with the study's evaluation criteria

18. Adult subject to a legal protection measure (guardianship, curatorship)

19. Person deprived of liberty by judicial or administrative decision

Date of first enrolment

05/04/2024

Date of final enrolment

22/09/2025

Locations

Countries of recruitment

United Kingdom

England

France

Italy

Study participating centre

NIHR Imperial Clinical Research Facility

Hammersmith Hospital

Du Cane Rd

Shepherd's Bush

London

England

W12 0HS

Study participating centre

Dipartimento di Agraria, Università degli Studi di Napoli Federico II

Via Università, 100

Portici

Italy

80055

Study participating centre

Centre de Recherche en Nutrition humaine Rhône-Alpes

Centre Hospitalier Lyon Sud - Bâtiment 2D CENS ELI

165 chemin du Grand Revoyet

Pierre-Bénite

France

69310

Sponsor information

Organisation

Imperial College London

ROR

<https://ror.org/041kmwe10>

Funder(s)

Funder type

Government

Funder Name

HORIZON EUROPE European Research Council

Alternative Name(s)

European Research Council, Horizon Europe - European Research Council, EU - Horizon Europe - ERC, European Research Council (ERC), Conseil européen de la recherche, Consejo Europeo de Investigación, Det Europæiske Forskningsråd, Europäischer Forschungsrat, ERC, CER, CEI, EFR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location**Funder Name**

UK Research and Innovation

Alternative Name(s)

UKRI

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes